Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

Angela Rose, European IVE group, Hanne‐Dorthe Emborg(Statens Serum Institut), Héloïse Lucaccioni, Mark G. O’Doherty(Public Health Agency), Kimberly Marsh(Joint United Nations Programme on HIV/AIDS), Francisco Pozo(Instituto de Salud Carlos III), Amanda Bolt Botnen(Statens Serum Institut), Mark Hamilton, Nick Andrews, Karina Lauenborg Møller, Safraj Shahul Hameed, Freja Kirsebom, Diogo F.P. Marques, Ramona Trebbien(Statens Serum Institut), Heather Whitaker(Public Health Agency of Canada)

Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

February 20, 2025

Cited by 0

Related Papers

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

|BMJ|2021|1.4k

Effect of Abolishment of the Use of Antimicrobial Agents for Growth Promotion on Occurrence of Antimicrobial Resistance in Fecal Enterococci from Food Animals in Denmark

|Antimicrobial Agents and Chemotherapy|2001|653

Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium

|BMJ|2015|551

Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020

|Eurosurveillance|2020|238

Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England

|medRxiv|2021|204